Aeterna Zentaris Balance Sheet Health
Financial Health criteria checks 6/6
Aeterna Zentaris has a total shareholder equity of $18.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $37.0M and $18.8M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$34.02m |
| Equity | US$18.20m |
| Total liabilities | US$18.82m |
| Total assets | US$37.02m |
Recent financial health updates
Recent updates
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aug 29Aeterna slips ~10% after announcing date of reverse stock split
Jul 19Aeterna Zentaris names Michael Teifel as chief scientific officer
May 03Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%
Feb 02Financial Position Analysis
Short Term Liabilities: AEZS's short term assets ($36.4M) exceed its short term liabilities ($4.5M).
Long Term Liabilities: AEZS's short term assets ($36.4M) exceed its long term liabilities ($14.3M).
Debt to Equity History and Analysis
Debt Level: AEZS is debt free.
Reducing Debt: AEZS has no debt compared to 5 years ago when its debt to equity ratio was 38.7%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AEZS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: AEZS has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 18.1% each year.